APEX1 and malignant colon neoplasm: For instance, the 70 proteins containing deleterious SAPs identified in the colon cancer samples, 11 are currently targets of FDA-approved drugs or drugs in clinical trials55, including APEX1, SERPINA1, and CASP7.